Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies
Participants receiving Foundayo lost 1.5% more body weight on average than those taking oral semaglutide.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance